Business Context and Reporting Period
Company: Context Therapeutics Inc. (CNTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Context is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. Key product candidates include CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3). The company has no product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8.68) million | $(4.58) million |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $54.53 million | $89.35 million |
| Cash Used in Operating Activities | $(11.43) million | $(5.03) million |
| Total Assets | $58.86 million | $68.49 million |
| Accumulated Deficit | $(139.58) million | $(99.36) million |
| Weighted Average Shares Outstanding | 95.18 million | 95.19 million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 90% (from $4.58 million to $8.68 million) primarily due to a 103% increase in Research and Development (R&D) expenses.
- R&D Expenses: R&D costs rose to $7.02 million from $3.46 million. Increases were driven by clinical trial costs for CTIM-76 (+$1.22M), CT-95 (+$0.62M), and CT-202 (+$0.92M), as well as higher personnel-related costs (+$0.78M).
- General and Administrative (G&A): G&A expenses increased 13% to $2.33 million, driven by higher salaries and share-based compensation.
- Interest Income: Decreased 46% to $0.52 million due to lower average cash balances.
- Liquidity: Cash and cash equivalents decreased by $11.47 million during the quarter, reflecting the burn rate required to fund clinical trials.
Guidance, Outlook, and Risks
- Cash Runway: Management believes cash of $54.5 million is sufficient to fund operations into mid-2027, covering Phase 1a trials for CTIM-76 and CT-95, and initiation of CT-202 trials.
- Capital Needs: The company anticipates incurring additional losses and will require substantial additional capital through equity offerings, debt, or collaborations to continue operations and commercialize products.
- Clinical Milestones:
- CTIM-76: Received FDA Fast Track designation for platinum-resistant ovarian cancer (April 2026). Phase 1a interim data expected in June 2026.
- CT-95: First patient dosed in April 2025. Phase 1a interim data expected in September 2026.
- CT-202: Received Australian regulatory approval. First patient dosing expected in Q3 2026.
- Legal Contingency: A stockholder class action regarding the Certificate of Incorporation was settled. A $0.9 million mootness fee was accrued and subsequently paid by a third-party service provider on behalf of the company.
- Risk Factors: Risks include the need for additional financing, clinical trial failures, regulatory delays, and potential intellectual property disputes (specifically regarding third-party patents related to CTIM-76).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $11.4 million quarterly operating cash burn against the stated mid-2027 runway.
- Financing Plans: Review the status of the At-The-Market (ATM) facility (up to $75 million aggregate) and any upcoming equity offerings.
- Clinical Data: Monitor the release of Phase 1a interim data for CTIM-76 (June 2026) and CT-95 (September 2026) for safety and efficacy signals.
- Intellectual Property: Assess the status of the third-party patent claims regarding CTIM-76 and the company's defense strategy.
- Legal Settlement: Confirm the final closure of the stockholder class action and ensure no further financial liabilities remain beyond the settled mootness fee.